Meeting
2023 ASCO Genitourinary Cancers Symposium
Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate in patients (pts) with advanced prostate cancer.
Authors
Jose W. Avitia
New Mexico Oncology Hematology Consultants Ltd., Albuquerque, NM
Jose W. Avitia , Ronald F. Tutrone , Neal D. Shore , James L. Bailen , Luke T. Nordquist , William Richardson , Cody J. Peer , William Douglas Figg , Jacqueline M. Walling , Joel Robert Eisner , Matthew Sharp , Robert Schotzinger , William R. Moore
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04729114
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 141)
DOI
10.1200/JCO.2023.41.6_suppl.141
Abstract #
141
Poster Bd #
E2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate, in patients (pts) with advanced prostate cancer.
First Author: Neal D. Shore
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate, in patients with prostate cancer including those previously treated with enzalutamide.
First Author: Jose W. Avitia
Poster
2022 ASCO Genitourinary Cancers Symposium
Abiraterone decanoate (PRL-02): Pharmacology of a single intramuscular (IM) depot injection compared to oral abiraterone acetate (AA) in intact male rats.
First Author: William R. Moore
Poster
2021 ASCO Annual Meeting
A phase 1/2a, open-label, multicenter study of intramuscular (IM) abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114).
First Author: Tim Warneke